SGLT2 Inhibitors – The New HF Therapies on the Block

Published: 25 August 2020

  • Views:

    Views Icon 374
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

In this Educational Symposium from the e-SPACE Heart Failure Global Web-Conference, Subodh Verma, Nikolaus Marx and Shelley Zieroth discuss SGLT2 inhibitors covering their history, a clinical perspective into what we have learned about them and how future trials might affect clinical practice. 

These videos were funded by an unrestricted educational grant from Boehringer Ingelheim & Eli Lilly and Company.

Learning objectives

  • Raise Awareness of SGLT2 Inhibitors as Cardiovascular Therapies With Cardio–Renal Benefits
  • Highlight Appropriate Patients for Initiation of an SGLT2 Inhibitor and Share With Cardiologists the Well-Established Safety Profile and Clinical Considerations for SGLT2 Inhibitor Treatment
  • Inform Cardiologists of the Current Evidence and Ongoing Trials for SGLT2 Inhibitors in Patients With HF

Agenda

  • 5 mins - Welcome & introduction - Subodh Verma
  • 15 mins - A brief history of SGLT2 inhibitors - Subodh Verma
  • 15 mins - What have we learned about SGLT2 inhibitors? A clinical perspective - Nikolaus Marx
  • 15 mins - How might future trials affect how I might treat my patients? - Shelley Zieroth
  • 10 mins - Faculty discussion (pre-recorded) - All Faculty
  • Close - Subodh Verma
  • Live Q&A and discussion - All Faculty

More from this programme

Part 1

Welcome & Introductions

Part 2

A Brief History of SGLT2 Inhibitors

Part 3

What Have We Learned About SGLT2 Inhibitors? A Clinical Perspective

Part 4

How Might Future Trials Affect How I Treat My Patients?

Part 5

Panel discussion

Faculty Biographies

Subodh Verma

Subodh Verma

Dr Subodh Verma is a cardiac surgeon-scientist at St Michael’s Hospital and Professor in the Departments of Surgery, and Pharmacology and Toxicity at the University of Toronto. He is also the current Canada Research Chair in Cardiovascular Surgery.

Dr Verma oversees a prolific basic, translational and clinical research program. He spearheads the CARDIOLINK clinical trials platform at St Michael’s Hospital and has leadership roles in seven ongoing global heart failure trials.

View full profile